By Robb M. Stewart
Unilever PLC's U.S.-listed stock retreated Tuesday as investors reacted to the company's efforts to push further into health, beauty and hygiene products with a $68 billion approach for GlaxoSmithKline PLC's consumer-health business.
In morning trading, the American depositary receipts were 11% lower at $48.41. They now stand down 10% in the new year, and 19% weaker over the last 12 months.
The maker of Dove soap and Ben & Jerry's ice cream over the weekend said it made a takeover approach for the business, which is 68% owned by Glaxo and 32% by Pfizer Inc. If successful, it would be Unilever's biggest-ever acquisition and the company said it would be accompanied by significant divestitures as it looks to shift its portfolio toward higher-growth categories.
Fitch Ratings on Tuesday cautioned an acquisition of the consumer-health business is likely to raise Unilever's debt to a level the company wouldn't be able to reduce it sufficiently to maintain an A rating category over 2024-2025, which could open the door to a multi-notch downgrade into the BBB category. Fitch said it believes Unilever's offer would need to be raised to be successful, given Glaxo's refusal to consider it, resulting in a further deterioration of the company's expected credit metrics.
Write to Robb M. Stewart at email@example.com
(END) Dow Jones Newswires